These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15575902)

  • 1. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients.
    Augustine JJ; Knauss TC; Schulak JA; Bodziak KA; Siegel C; Hricik DE
    Am J Transplant; 2004 Dec; 4(12):2001-6. PubMed ID: 15575902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of azathioprine and mycophenolate mofetil-immunosuppressive regimens on the erythropoietic system of renal transplant recipients.
    Khosroshahi HT; Asghari A; Estakhr R; Baiaz B; Ardalan MR; Shoja MM
    Transplant Proc; 2006 Sep; 38(7):2077-9. PubMed ID: 16980004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco.
    Vincenti F; Stock P
    Transplant Proc; 2003 May; 35(3 Suppl):183S-186S. PubMed ID: 12742494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
    Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
    Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines.
    Morrone LF; Di Paolo S; Logoluso F; Schena A; Stallone G; Giorgino F; Schena FP
    Transplantation; 1997 Sep; 64(6):913-8. PubMed ID: 9326420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation.
    Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU
    Am J Transplant; 2007 Mar; 7(3):586-94. PubMed ID: 17229066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential differences in kidney allograft outcomes between ethnicities when converting to sirolimus base immunosuppression.
    Patel N; Taber DJ; Weimert NA; Fleming JN; Egidi FM; McGillicuddy J; Bratton CF; Lin A; Chavin KD; Baliga PK
    Transplant Proc; 2009 Dec; 41(10):4131-7. PubMed ID: 20005354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
    Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoiesis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells.
    Lezaic V; Biljanovic-Paunovic L; Pavlovic-Kentera V; Djukanovic L
    Eur J Med Res; 2001 Jan; 6(1):27-32. PubMed ID: 11313188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National survey of anemia prevalence after kidney transplantation in Argentina.
    Petrone H; Arriola M; Re L; Taylor F; Bruzzone M; Chiurchu C; Schiavelli R;
    Transplant Proc; 2010; 42(1):288-90. PubMed ID: 20172333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.